SUMMARY Using a recently developed chromogenic substrate assay sensitive to 10 pg/ml Escherichia coli endotoxin in plasma, systemic endotoxaemia was found in 52% of 21 episodes of fever in patients with a haematological malignancy who were infected. Endotoxaemia was also found in 27% of 22 episodes of fever of unknown origin. In 45 afebrile patients neither neutropenia nor cytotoxic chemotherapy was a cause of endotoxaemia. Passage of endotoxin from portal blood into the systemic circulation can contribute to unexplained fever in immunosuppressed patients.
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In man the normal bowel flora constitutes a large reservoir of bacterial endotoxin with the potential to cause portal venous endotoxaemia.' Any endotoxin present in portal blood is normally destroyed by peroxidases and esterases present in hepatic fixed macrophage (Kupffer) cells and thus does not reach the systemic circulation.2 In cirrhosis and in Reye's syndrome, however, systemic endotoxaemia without bacteraemia has been shown' 3 and has been ascribed to Kupffer cell dysfunction45 or intrahepatic portal-systemic shunting of blood.6
In haematological malignancy systemic endotoxaemia without bacteraemia could occur as a consequence of intestinal mucosal damage by cytotoxic agents, or because of a numerical or functional defect of neutrophils, or because of impaired hepatic reticuloendothelial cell clearance of endotoxin. Episodes of fever are common in these patients and often remain unexplained despite intensive microbiological investigation. We have therefore determined the incidence of endotoxaemia, as measured by a new chromogenic substrate assay, in patients with haematological malignancy and have studied the relation between endotoxaemia and the development of fever.
Patients and methods

PATIENTS
Endotoxin assays were carried out on 27 healthy subjects (18 men, nine women) and 32 outpatients Accepted for publication 2 December 1983 (10 men, 22 women) with a non-malignant haematological disorder. One hundred patients (54 men, 46 women) with the following haematological malignancies were also studied: acute myeloblastic leukaemia (21 patients), acute lymphoblastic leukaemia (13 
Results
The 27 healthy subjects all gave endotoxin assay values in the range 0-0-15 OD units. The same reference range was obtained for 31 of the 32 outpatients with a non-malignant haematological disorder and 58 of the 60 outpatients with a haematological malignancy who were not taking cytotoxic drugs and were not neutropenic. These three exceptions (endotoxin values in the range 0-17-0-25 OD units) are shown in Fig. 1 , where the three groups have been amalgamated to give a reference group of 119 individuals. To determine the effects of neutropenia and cytotoxic chemotherapy on this reference range endotoxin assays were performed on 75 plasma specimens from 45 afebrile outpatients with a haematological malignancy, who were subdivided as follows: Group I-currently receiving cytotoxic agents but not severely neutropenic (mean neutrophil count 3-7 x 109/1; range 1.1-6.8) Group II-neutropenic (mean neutrophil count 0-4 x 109/1; range 0-0-9) but no cytotoxic agents given for at least three days before study Group III-currently receiving cytotoxic agents and also neutropenic (mean neutrophil count 0-4 x 109/ I; range 0-0.9) There was no significant difference (p > 0.1) in plasma endotoxin values between these three groups or between any one of them and the reference group (Fig. 1) Endotoxin assays were performed within 24 h of the onset of 43 episodes of fever (mean oral temperature 38 4°C, range 37-5-39 8°C) in 29 inpatients with haematological malignancy. In 21 episodes of fever in which there was clinical or laboratory evidence of infection, or both, 11 showed plasma endotoxin activity greater than 0.15 OD units (Fig.  2) . These episodes comprised Gram negative septicaemia (5 cases), Gram positive septicaemia (2 cases), respiratory infection (2 cases), and unidentified infection causing a rise in C reactive protein concentration to greater than 150 mg/l (2 cases). An episode of unexplained fever was defined as: absence of clinical signs of infection together with negative bacteriological cultures, maximum serum C reactive protein concentration less than 100 mg/l, negative viral antibody titres, and no temporal relation to administration of blood products. Twenty two such episodes were identified and six had endotoxin assay results greater than 0-15 OD units (Fig. 2) .
Serial endotoxin assays were undertaken during 12 episodes of fever showing initial endotoxin values of more than 0 15 OD units; endotoxaemia and fever failed to resolve in parallel in 11 of these episodes (Fig. 3 ). In the six endotoxaemic patients with unexplained fever, endotoxin assay results fell to less than 0 15 OD units within 48 h; in three of these pafients the fever also resolved within 48 h but Endotoxaemia as a cause offever in immunosuppressed patients in two it was sustained for five to se of seven episodes of clinically e' without fever showed transiently r activity in five. A close temporal ri endotoxaemia and fever was not t lished in any of these groups.
Most of the earlier clinical studies of endotoxaemia used the Limulus gelation assay, which has the disadvantages of poor specificity, subjective end point, and relative lack of sensitivity. The improved chromogenic substrate assay developed for the present study links the activation of the Limulus amoebocyte proenzyme to a chromogenic substrate, thus bypassing the gelation reaction. This assay is more sensitive (to 10 pg/ml Escherichia coli endotoxin in plasma), specific, and reproducible (within batch coefficient of variation of 4%).' Contamination with extraneous endotoxin, which may have occurred in earlier studies, was minimised by performing the assay in a laminar air flow cabinet and by using new, endotoxin free tubes for each test. 
